Lu Bai, Shuhua Zhao, Jia Xu, Yan Gao, Yuanyuan He, Yanjie Ren, Xiaohong Zhang
{"title":"晚期卵巢癌新辅助化疗后间歇减容手术的手术效果及预后因素分析。","authors":"Lu Bai, Shuhua Zhao, Jia Xu, Yan Gao, Yuanyuan He, Yanjie Ren, Xiaohong Zhang","doi":"10.62347/LKZC2827","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the surgical outcomes and prognostic factors of neoadjuvant chemotherapy (NACT) combined with interval debulking surgery (IDS) in patients with advanced ovarian cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on clinical data of 97 patients with advanced ovarian cancer admitted to Xijing Hospital of The Fourth Military Medical University from January 2018 to December 2019. The patients were divided into two groups based on their treatment methods: a control group (primary debulking surgery (PDS), n=48) and an observation group (NACT combined with IDS, n=49). Short-term efficacy, perioperative outcomes, tumor markers, immune function, quality of life, adverse reactions, and survival status were compared between the two groups. Factors affecting prognosis were analyzed, a Nomogram prediction model was constructed and validated.</p><p><strong>Results: </strong>The observation group demonstrated superior short-term efficacy than the control group, with lower intraoperative blood loss, shorter hospitalization duration, and reduced transfusion volume (<i>P</i><0.05). After treatment, tumor marker levels, immune function, and quality of life improved significantly in both groups compared to pre-treatment levels, with more pronounced improvements in the observation group (<i>P</i><0.05). The incidence of adverse reactions such as liver injury, kidney injury, nausea and vomiting, and myelosuppression was lower in the observation group than in the control group (<i>P</i><0.05). Additionally, no significant difference in 5-year progression-free survival (PFS) and overall survival (OS) was observed between the two groups (<i>P</i>>0.05). Univariate and multivariate regression analyses identified age ≥50 years, tumor size >10 cm, low differentiation, PDS, and presence of residual lesions as independent prognostic factors. The Nomogram prediction model achieved an AUC of 0.955 (95% CI: 0.917-0.993), with calibration curves closely aligning with the ideal line, indicating high predictive accuracy and reliability.</p><p><strong>Conclusion: </strong>NACT combined with IDS demonstrated superior short-term efficacy compared to traditional PDS in patients with advanced ovarian cancer, with improved perioperative conditions, reduced adverse reactions, and enhanced survival rates. Age, tumor size, histological differentiation, and treatment modality independently affect patient prognosis. The Nomogram prediction model developed in this study demonstrates excellent discriminative power and clinical applicability for prognostic evaluation.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3603-3616"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432551/pdf/","citationCount":"0","resultStr":"{\"title\":\"Surgical outcomes and prognostic factors of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.\",\"authors\":\"Lu Bai, Shuhua Zhao, Jia Xu, Yan Gao, Yuanyuan He, Yanjie Ren, Xiaohong Zhang\",\"doi\":\"10.62347/LKZC2827\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the surgical outcomes and prognostic factors of neoadjuvant chemotherapy (NACT) combined with interval debulking surgery (IDS) in patients with advanced ovarian cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on clinical data of 97 patients with advanced ovarian cancer admitted to Xijing Hospital of The Fourth Military Medical University from January 2018 to December 2019. The patients were divided into two groups based on their treatment methods: a control group (primary debulking surgery (PDS), n=48) and an observation group (NACT combined with IDS, n=49). Short-term efficacy, perioperative outcomes, tumor markers, immune function, quality of life, adverse reactions, and survival status were compared between the two groups. Factors affecting prognosis were analyzed, a Nomogram prediction model was constructed and validated.</p><p><strong>Results: </strong>The observation group demonstrated superior short-term efficacy than the control group, with lower intraoperative blood loss, shorter hospitalization duration, and reduced transfusion volume (<i>P</i><0.05). After treatment, tumor marker levels, immune function, and quality of life improved significantly in both groups compared to pre-treatment levels, with more pronounced improvements in the observation group (<i>P</i><0.05). The incidence of adverse reactions such as liver injury, kidney injury, nausea and vomiting, and myelosuppression was lower in the observation group than in the control group (<i>P</i><0.05). Additionally, no significant difference in 5-year progression-free survival (PFS) and overall survival (OS) was observed between the two groups (<i>P</i>>0.05). Univariate and multivariate regression analyses identified age ≥50 years, tumor size >10 cm, low differentiation, PDS, and presence of residual lesions as independent prognostic factors. The Nomogram prediction model achieved an AUC of 0.955 (95% CI: 0.917-0.993), with calibration curves closely aligning with the ideal line, indicating high predictive accuracy and reliability.</p><p><strong>Conclusion: </strong>NACT combined with IDS demonstrated superior short-term efficacy compared to traditional PDS in patients with advanced ovarian cancer, with improved perioperative conditions, reduced adverse reactions, and enhanced survival rates. Age, tumor size, histological differentiation, and treatment modality independently affect patient prognosis. The Nomogram prediction model developed in this study demonstrates excellent discriminative power and clinical applicability for prognostic evaluation.</p>\",\"PeriodicalId\":7437,\"journal\":{\"name\":\"American journal of cancer research\",\"volume\":\"15 8\",\"pages\":\"3603-3616\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432551/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/LKZC2827\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/LKZC2827","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Surgical outcomes and prognostic factors of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Objective: To investigate the surgical outcomes and prognostic factors of neoadjuvant chemotherapy (NACT) combined with interval debulking surgery (IDS) in patients with advanced ovarian cancer.
Methods: A retrospective analysis was conducted on clinical data of 97 patients with advanced ovarian cancer admitted to Xijing Hospital of The Fourth Military Medical University from January 2018 to December 2019. The patients were divided into two groups based on their treatment methods: a control group (primary debulking surgery (PDS), n=48) and an observation group (NACT combined with IDS, n=49). Short-term efficacy, perioperative outcomes, tumor markers, immune function, quality of life, adverse reactions, and survival status were compared between the two groups. Factors affecting prognosis were analyzed, a Nomogram prediction model was constructed and validated.
Results: The observation group demonstrated superior short-term efficacy than the control group, with lower intraoperative blood loss, shorter hospitalization duration, and reduced transfusion volume (P<0.05). After treatment, tumor marker levels, immune function, and quality of life improved significantly in both groups compared to pre-treatment levels, with more pronounced improvements in the observation group (P<0.05). The incidence of adverse reactions such as liver injury, kidney injury, nausea and vomiting, and myelosuppression was lower in the observation group than in the control group (P<0.05). Additionally, no significant difference in 5-year progression-free survival (PFS) and overall survival (OS) was observed between the two groups (P>0.05). Univariate and multivariate regression analyses identified age ≥50 years, tumor size >10 cm, low differentiation, PDS, and presence of residual lesions as independent prognostic factors. The Nomogram prediction model achieved an AUC of 0.955 (95% CI: 0.917-0.993), with calibration curves closely aligning with the ideal line, indicating high predictive accuracy and reliability.
Conclusion: NACT combined with IDS demonstrated superior short-term efficacy compared to traditional PDS in patients with advanced ovarian cancer, with improved perioperative conditions, reduced adverse reactions, and enhanced survival rates. Age, tumor size, histological differentiation, and treatment modality independently affect patient prognosis. The Nomogram prediction model developed in this study demonstrates excellent discriminative power and clinical applicability for prognostic evaluation.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.